Cixutumumab (Anti-IGF1R / CD221) is a humanized monoclonal antibody with high affinity that targets type-1-insulin-like growth factor receptor (IGF-1R).It shows broad-spectrum anti-tumour activity and can be used in studies of sarcomas, neuroblastoma, wilms tumor, lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer. MW :150 KD.